Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

efavirenz-lamiVUDine-tenofovir disoproxil fumarate

efavirenz-lamiVUDine-tenofovir disoproxil fumarate
  • Non-formulary
  • Therapeutic Interchange
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Symfi Lo TABLET, ORAL 400 mg-300 mg- 300 mg    
Symfi TABLET, ORAL 600 mg-300 mg-300 mg    
Comments:

ORDERED FORMULATION

THERAPEUTIC INTERCHANGE
efavirenz-lamiVUDine-tenofovir disoproxil fumarate

(Symfi)

  • 600 mg-300 mg-300 mg oral tablet

efavirenz (Sustiva) and lamiVUDine (Epivir) and tenofovir disoproxil fumarate (Viread)

  • THREE 200 mg efavirenz PLUS ONE 300 mg lamiVUDine oral tablet PLUS ONE 300 mg tenofovir disoproxil fumarate oral tablet
efavirenz-lamiVUDine-tenofovir disoproxil fumarate

(Symfi Lo)

  • 400 mg-300 mg-300 mg oral tablet

efavirenz (Sustiva) and lamiVUDine (Epivir) and tenofovir disoproxil fumarate (Viread)

  • TWO 200 mg efavirenz PLUS ONE 300 mg lamiVUDine oral tablet PLUS ONE 300 mg tenofovir disoproxil fumarate oral tablet

Symfi and Symfi Lo are non-formulary. Automatic interchange to equivalent single drug products.

Reviewed: 28 Aug 2018 (Symfi & Symfi Lo)

Last updated: Sep. 27, 2018






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved